Recursion Pharmaceuticals, Inc. (RXRX)
| Previous close | 8.79 |
| Open | 9.24 |
| Bid | 9.14 x 1600 |
| Ask | 11.57 x 200 |
| Day's range | 9.02 - 9.40 |
| 52-week range | 4.92 - 16.75 |
| Volume | |
| Avg. volume | 6,390,832 |
| Market cap | 2.178B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
ZacksRecursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GlobeNewswireRecursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
Company to host public L(earnings) Call on May 9 at 5:00 pm ETSALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern
GlobeNewswireRecursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities Healthcare Conference – May 14-16, 202452nd Annual JP Morgan Global Technology Conference – May 20-22, 2024 About Recursion Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug disc
